imgboxbg

News

Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-06-18 08:00
  • Views:221

Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-06-18 08:00
  • Views:221
Information

IASO Biotherapeutics (IASO Bio),one of the top biotechnology innovators, announced that potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology,the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago Illinois,May 31-June 4[Abstract#8013; Tuesday,June 4,CDT],and the 24th Congress of the European Hematological Society (EHA),June 13–16[Abstract#S827;Saturday,June 15,12:35 PM-12:45 PM CEST].

As the top and most influential international oncology conference, these notable meetings feature the efforts of the brightest minds driving innovation in hematology and cancer research from around the globe. With a combined international attendance of more than 50,000, this year’s meetings focused heavily on the field of immunotherapy, presenting the late